Clinical Trial: A single-center, open-label, single-arm, prospective clinical study of eponemine combined with bortezomib, lenalidomide, dexamethasone (Apo-VRd) regimen in the treatment of newly diagnosed multiple myeloma patients with high-risk factors (China)

China, Nov. 10 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A single-center, open-label, single-arm, prospective clinical study of eponemine combined with bortezomib, lenalidomide, dexamethasone (Apo-VRd) regimen in the treatment of newly diagnosed multiple myeloma patients with high-risk factors'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600136160

Registration Time: 2026/11/06

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital, College of Medicine, Zhejiang University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=345664

Published by HT Digital Content Services with permission from H...